Eli Lilly and Company's Melissa Barnes, who chairs the Ethics and Business Integrity Committee (eBIC) at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and Thomas Cueni, the organisation’s director general, outline the key features of the IFPMA’s ambitious new Code of Practice and discuss the state of ethics and business integrity within the global pharmaceutical industry today.
When one looks at patient expectations and rule-setting from government, companies that misstep will, sooner or later, be called to order. The research-based pharmaceutical industry is expected to lead. - Thomas Cueni
